Search: onr:"swepub:oai:DiVA.org:liu-198833" >
A Markov model of f...
A Markov model of fibrosis development in nonalcoholic fatty liver disease predicts fibrosis progression in clinical cohorts
-
- Knochel, Jane (author)
- AstraZeneca, Sweden
-
- Bergenholm, Linnea (author)
- AstraZeneca, Sweden
-
- Ibrahim, Eman (author)
- Uppsala Univ, Sweden
-
show more...
-
- Kechagias, Stergios (author)
- Linköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Mag- tarmmedicinska kliniken
-
- Hansson, Sara (author)
- AstraZeneca, Sweden
-
- Liljeblad, Mathias (author)
- AstraZeneca, Sweden
-
- Nasr, Patrik (author)
- Linköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Mag- tarmmedicinska kliniken
-
- Carlsson, Bjorn (author)
- AstraZeneca, Sweden
-
- Ekstedt, Mattias (author)
- Linköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Mag- tarmmedicinska kliniken
-
- Ueckert, Sebastian (author)
- AstraZeneca, Sweden
-
show less...
-
(creator_code:org_t)
- WILEY, 2023
- 2023
- English.
-
In: CPT. - : WILEY. - 2163-8306. ; 12:12, s. 2038-2049
- Related links:
-
https://liu.diva-por... (primary) (Raw object)
-
show more...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Disease progression in nonalcoholic steatohepatitis (NASH) is highly heterogenous and remains poorly understood. Fibrosis stage is currently the best predictor for development of end-stage liver disease and mortality. Better understanding and quantifying the impact of factors affecting NASH and fibrosis is essential to inform a clinical study design. We developed a population Markov model to describe the transition probability between fibrosis stages and mortality using a unique clinical nonalcoholic fatty liver disease cohort with serial biopsies over 3 decades. We evaluated covariate effects on all model parameters and performed clinical trial simulations to predict the fibrosis progression rate for external clinical cohorts. All parameters were estimated with good precision. Age and diagnosis of type 2 diabetes (T2D) were found to be significant predictors in the model. Increase in hepatic steatosis between visits was the most important predictor for progression of fibrosis. Fibrosis progression rate (FPR) was twofold higher for fibrosis stages 0 and 1 (F0-1) compared to fibrosis stage 2 and 3 (F2-3). A twofold increase in FPR was observed for T2D. A two-point steatosis worsening increased the FPR 11-fold. Predicted fibrosis progression was in good agreement with data from external clinical cohorts. Our fibrosis progression model shows that patient selection, particularly initial fibrosis stage distribution, can significantly impact fibrosis progression and as such the window for assessing drug efficacy in clinical trials. Our work highlights the increase in hepatic steatosis as the most important factor in increasing FPR, emphasizing the importance of well-defined lifestyle advise for reducing variability in NASH progression during clinical trials.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Farmaceutiska vetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Pharmaceutical Sciences (hsv//eng)
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
-
CPT
(Search for host publication in LIBRIS)
To the university's database
- By the author/editor
-
Knochel, Jane
-
Bergenholm, Linn ...
-
Ibrahim, Eman
-
Kechagias, Sterg ...
-
Hansson, Sara
-
Liljeblad, Mathi ...
-
show more...
-
Nasr, Patrik
-
Carlsson, Bjorn
-
Ekstedt, Mattias
-
Ueckert, Sebasti ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Basic Medicine
-
and Pharmaceutical S ...
- Articles in the publication
-
CPT
- By the university
-
Linköping University